Patient and transplant characteristics
| . | HLA-DPB1 ΔFD ≤2.665 . | HLA-DPB1 ΔFD >2.665 . | . |
|---|---|---|---|
| . | N (%) . | N (%) . | P* . |
| Number of patients | 252 (67) | 127 (33) | — |
| Recipient age, median (range) | 53 (19-73) | 52 (19-71) | NS |
| Age at transplant | |||
| <Median age (53 y) | 122 (48) | 67 (53) | NS |
| ≥Median age (53 y) | 130 (52) | 60 (47) | — |
| Male sex | 130 (52) | 63 (50) | NS |
| Disease at transplant | |||
| AML | 177 (70) | 95 (75) | NS |
| ALL | 39 (15) | 19 (15) | — |
| MDS | 36 (14) | 13 (10) | — |
| Disease status at transplant | |||
| Early | 112 (44) | 53 (42) | NS |
| Intermediate | 60 (24) | 29 (23) | — |
| Advanced | 80 (32) | 45 (35) | — |
| Graft type | |||
| Bone marrow | 14 (6) | 6 (5) | NS |
| PBSC | 238 (94) | 121 (95) | — |
| Conditioning regimen | |||
| Myeloablative | 124 (49) | 58 (46) | NS |
| Reduced intensity | 128 (51) | 69 (54) | — |
| In vivo T-cell depletion (ATG) | |||
| Yes | 135 (64) | 56 (44) | NS |
| No | 117 (46) | 71 (56) | — |
| Donor/recipient sex match | |||
| Female/male | 15 (6) | 10 (8) | NS |
| Others | 237 (94) | 117 (92) | — |
| Donor/recipient CMV match | |||
| Negative/negative | 77 (30) | 36 (28) | NS |
| Positive/positive | 102 (40) | 46 (36) | NS |
| Positive/negative | 13 (5) | 9 (7) | — |
| Negative/positive | 60 (24) | 36 (28) | — |
| Donor age, median (range) | 35 (18-59) | 36 (18-58) | NS |
| Number of HLA-DPB1 allele mismatches | |||
| 1 | 194 (77) | 59 (46) | <.0001 |
| 2 | 58 (23) | 68 (54) | — |
| HLA-DPB1 TCE status | |||
| Matched (permissive) | 189 (75) | 15 (12) | <.0001 |
| Mismatched (nonpermissive) | 63 (25) | 112 (88) | — |
| HLA-DPB1 ΔFD, median (range) | 1.12 (0.01-2.66) | 3.47 (2.67-7.46) | <.0001 |
| . | HLA-DPB1 ΔFD ≤2.665 . | HLA-DPB1 ΔFD >2.665 . | . |
|---|---|---|---|
| . | N (%) . | N (%) . | P* . |
| Number of patients | 252 (67) | 127 (33) | — |
| Recipient age, median (range) | 53 (19-73) | 52 (19-71) | NS |
| Age at transplant | |||
| <Median age (53 y) | 122 (48) | 67 (53) | NS |
| ≥Median age (53 y) | 130 (52) | 60 (47) | — |
| Male sex | 130 (52) | 63 (50) | NS |
| Disease at transplant | |||
| AML | 177 (70) | 95 (75) | NS |
| ALL | 39 (15) | 19 (15) | — |
| MDS | 36 (14) | 13 (10) | — |
| Disease status at transplant | |||
| Early | 112 (44) | 53 (42) | NS |
| Intermediate | 60 (24) | 29 (23) | — |
| Advanced | 80 (32) | 45 (35) | — |
| Graft type | |||
| Bone marrow | 14 (6) | 6 (5) | NS |
| PBSC | 238 (94) | 121 (95) | — |
| Conditioning regimen | |||
| Myeloablative | 124 (49) | 58 (46) | NS |
| Reduced intensity | 128 (51) | 69 (54) | — |
| In vivo T-cell depletion (ATG) | |||
| Yes | 135 (64) | 56 (44) | NS |
| No | 117 (46) | 71 (56) | — |
| Donor/recipient sex match | |||
| Female/male | 15 (6) | 10 (8) | NS |
| Others | 237 (94) | 117 (92) | — |
| Donor/recipient CMV match | |||
| Negative/negative | 77 (30) | 36 (28) | NS |
| Positive/positive | 102 (40) | 46 (36) | NS |
| Positive/negative | 13 (5) | 9 (7) | — |
| Negative/positive | 60 (24) | 36 (28) | — |
| Donor age, median (range) | 35 (18-59) | 36 (18-58) | NS |
| Number of HLA-DPB1 allele mismatches | |||
| 1 | 194 (77) | 59 (46) | <.0001 |
| 2 | 58 (23) | 68 (54) | — |
| HLA-DPB1 TCE status | |||
| Matched (permissive) | 189 (75) | 15 (12) | <.0001 |
| Mismatched (nonpermissive) | 63 (25) | 112 (88) | — |
| HLA-DPB1 ΔFD, median (range) | 1.12 (0.01-2.66) | 3.47 (2.67-7.46) | <.0001 |
ΔFD, δ-functional distance; NS, not significant; PBSC, peripheral blood mobilized stem cell.
The Wilcoxon rank-sum test was used to test differences of continuous variables. Differences in frequencies of discrete variables were tested by the two-sided Fisher’s exact test.